TY - JOUR
T1 - Metallopanstimulin as a marker for head and neck cancer
AU - Stack, Brendan C.
AU - Hollenbeak, Christopher S.
AU - Lee, Christopher M.
AU - Dunphy, Frank R.
AU - Lowe, Val J.
AU - Hamilton, Paul D.
PY - 2004/12/14
Y1 - 2004/12/14
N2 - Background: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts in the sera of patients with head and neck squamous cell carcinoma (HNSCC). We used a test, denoted MPS-H, which detects MPS-1 and MPS-1-like proteins, to determine the relationship between MPS-H serum levels and clinical status of patients with, or at risk for, HNSCC. Patients and methods: A total of 125 patients were prospectively enrolled from a university head and neck oncology clinic. Participants included only newly diagnosed HNSCC patients. Two control groups, including 25 non-smokers and 64 smokers, were studied for comparison. A total of 821 serum samples collected over a twenty-four month period were analyzed by the MPS-H radioimmunoassay. Results: HNSCC, non-smokers, and smokers had average MPS-H values of 41.5 ng/mL, 10.2 ng/mL, and 12.8 ng/mL, respectively (p = 0.0001). Conclusion: We conclude that MPS-1 and MPS-1-like proteins are elevated in patients with HNSCC, and that MPS-H appears to be a promising marker of presence of disease and response to treatment in HNSCC patients.
AB - Background: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts in the sera of patients with head and neck squamous cell carcinoma (HNSCC). We used a test, denoted MPS-H, which detects MPS-1 and MPS-1-like proteins, to determine the relationship between MPS-H serum levels and clinical status of patients with, or at risk for, HNSCC. Patients and methods: A total of 125 patients were prospectively enrolled from a university head and neck oncology clinic. Participants included only newly diagnosed HNSCC patients. Two control groups, including 25 non-smokers and 64 smokers, were studied for comparison. A total of 821 serum samples collected over a twenty-four month period were analyzed by the MPS-H radioimmunoassay. Results: HNSCC, non-smokers, and smokers had average MPS-H values of 41.5 ng/mL, 10.2 ng/mL, and 12.8 ng/mL, respectively (p = 0.0001). Conclusion: We conclude that MPS-1 and MPS-1-like proteins are elevated in patients with HNSCC, and that MPS-H appears to be a promising marker of presence of disease and response to treatment in HNSCC patients.
UR - http://www.scopus.com/inward/record.url?scp=13844297747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13844297747&partnerID=8YFLogxK
U2 - 10.1186/1477-7819-2-45
DO - 10.1186/1477-7819-2-45
M3 - Article
AN - SCOPUS:13844297747
SN - 1477-7819
VL - 2
JO - World Journal of Surgical Oncology
JF - World Journal of Surgical Oncology
M1 - 45
ER -